• Biomolecules & Therapeutics
• /
• 제7권2호
• /
• pp.198-203
• /
• 1999

Loxoprofen-Na (sodium 2-〔4-(2-oxocyclopentylmethyl)pheny)propionate dihydrate) is a potent analgesic drug. We developed loxoprofen-Na plasters to extend duration time of analgesic activity and to reduce side effect on gastrointestinal tract. Analgesic effect of Loxoprofen-Na plasters was investigated. Loxoprofen-Na plaster had good analgesic effect in rat paw pressure test, Tail-flick latency test and acetic acid-induced writhing test. Also, it had anti-inflammatory effect on carrageenan-induced rat hind paw edema. In pharmacokinetic study of Loxoprofen-Na, plasters dosage form showed that plasma drug concentration was prolonged up to 14 hours. So, we can conclude that loxoprofen-Na plasters, when applied on skin, will be a new type of drug for controlling the various local pain or inflammation.

• Journal of Pharmaceutical Investigation
• /
• 제41권6호
• /
• pp.347-354
• /
• 2011

Repeated oral administration of loxoprofen can induce many side effects such as gastric disturbances and acidosis. Therefore, we considered alternative routes of administration for loxoprofen to avoid such adverse effects. The aim of this study was to develop an ethylene-vinyl acetate (EVA) matrix system containing a permeation enhancer for enhanced transdermal delivery of loxoprofen. The EVA matrix containing loxoprofen was fabricated and the effects of drug concentration, temperature, enhancer and plasticizer on drug release were studied from the loxoprofen-EVA matrix. The solubility of loxoprofen was highest at 40% (v/v) PEG 400. The release rate of drug from drug-EVA matrix increased with increased loading dose and temperature. The release rate was proportional to the square root of loading dose. The activation energy (Ea), which was measured from the slope of log P versus 1000/T, was 5.67 kcal/mol for a 2.0% loaded drug dose from the EVA matrix. Among the plasticizer used, diethyl phthalate showed the highest release rate of loxoprofen. Among the enhancers used, polyoxyethylene 2-oleyl ether showed the greatest enhancing effect. In conclusion, for the enhanced controlled transdermal delivery of loxoprofen, the application of the EVA matrix containing plasticizer and penetration enhancer could be useful in the development of a controlled drug delivery system.

• Biomolecules & Therapeutics
• /
• 제6권4호
• /
• pp.417-422
• /
• 1998

Loxoprofen sodium (sodium 2-[4-(2-oxocyclopentylmethyl)phenyl] propionate dehydrate) is a nonsteroidal antiinflammatory drug of $\alpha$-phenyl propionic acid derivative. To test the bioequivalence of loxoprofen, the pharmacokinetic parameters of new preparation of loxoprofen, LENOX was compared with LOXONIN as a reference drug. Fourteen healthy volunteers were entered to the stydy (Yonsei University College of Medicine, Severance Hospital IRB approval No. 9608). They were administered 60 mg of loxoprofen in 2$\times$2 cross-over design. There was one week of drug-free interval between doses. The blood sample was taken on schedule up to 8 hours, and the plasma concentration loxoprofen was measured by reverse phase high-performance liquid chromatography (HPLC) with UV-detector. There were no significant difference between two preparations when AUC, Cmax, and Tmax were compared by ANOVA. The mean differences of AUC, Cmax, and Tmax were within 20% of the reference drug: the values were 2.22,5.61, and 12.50%, respectively. The confidence limits of AUC and Cmax but not Tmax satisfied the bioequivalence criteria. These results suggest that the tested LENOX is bioequivalent to the reference drug.

• Journal of Pharmaceutical Investigation
• /
• 제41권2호
• /
• pp.117-123
• /
• 2011

Loxoprofen sodium, a 2-phenylpropionate non-steroidal anti-inflammatory drug (NSAID), has marked analgesic and antipyretic activities and relatively weak gastrointestinal ulcerogenicity. The purpose of the present study was to evaluate the bioequivalence of two loxoprofen sodium tablets, Hana loxoprofen sodium tablet (Hana Pharm. Co., Ltd.) and Dongwha Loxonin$^{(R)}$ tablet (Dongwha Pharm. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The in vitro release of loxoprofen from the two loxoprofen sodium formulations was tested using KP IX Apparatus II method with various dissolution media. Twenty four healthy Korean male volunteers, $22.83{\pm}1.862$ years in age and $69.92{\pm}9.14$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ crossover study was employed. After a single tablet containing 60 mg as loxoprofen sodium was orally administered, blood samples were taken at predetermined time intervals and the concentrations of loxoprofen in serum were determined using a online column-switching HPLC method with UV/Vis detection. The dissolution profiles of two formulations were similar in all tested dissolution media. The pharmacokinetic parameters such as $AUC^t$, $C_{max}$ and $T_{max}$ were calculated, and computer programs (Equiv Test and K-BE Test 2002) were utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and un-transformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, Dongwha Loxonin$^{(R)}$ tablet, were 2.03, 2.99 and -9.49% for $AUC_t$, $C_{max}$, and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log0.8 to log1.25 (e.g., log0.9831~log1.0535 and log0.9455~log1.1386 for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Hana loxoprofen sodium tablet was bioequivalent to Dongwha Loxonin$^{(R)}$ tablet.

• KSBB Journal
• /
• 제21권5호
• /
• pp.371-375
• /
• 2006

본 실험의 목적은 frontal analysis(FA)와 pluse input method(PIM) 방법으로 흡착분리공정에 있어서 중요한 전 단계의 하나인 등온흡착식을 결정하는데 있다. FA를 수행하기에 앞서 대상물질이었던 loxoprofen의 용해도를 측정하여 hexane/ethanol=95/5일 때 시료의 농도를 $0.2{\sim}3mg/ml$로 결정하고, pH조정을 위한 acetic acid는 0.5%로 결정하였다. 이동상의 주성분인 hexane의 조성이 증가함에 따라 용해도는 감소하였지만 분리도는 증가하는 경향을 확인하였다. 이런 용해도와 분리도 사이의 trade-off 또한 흡착분리과정에서의 조작변수가 될 수 있음을 의미한다. FA로 구한 이성분계 등온흡착식은 $$C_{S,re}=\frac{5.282C_{M,re}}{1+0.1412C_{M,re}+0.2139C_{M,ex}}$$, $$C_{S,ex}=\frac{6.413C_{M,ex}}{1+0.2139C_{M,ex}+0.1412C_{M,re}}$$로 결정하였고, PIM으로 구한 이성분계 등온흡착식은 $$C_{S,re}=\frac{5.245C_{M,re}}{1+0.1667C_{M,re}+0.2054C_{M,ex}}$$, $$C_{S,ex}=\frac{6.061C_{M,ex}}{1+0.2054C_{M,ex}+0.1667C_{M,re}}$$로 결정 하였다.

• Korean Chemical Engineering Research
• /
• 제49권5호
• /
• pp.623-627
• /
• 2011

Loxoprofen racemate를 분리하기 위해 SMB에서 운전조건을 탐색하였다. Aspen simulator를 이용하여 전산모사를 함으로써 loxoprofen racemate를 분리할 수 있는 운전조건을 다음과 같이 제시할 수 있었다. Raffinate 순도를 증가시키기 위해 삼각도에서 왼쪽 중간 부분의 $m_2$, $m_3$ 좌표를 정하여야 하며 내부농도 분포도에서 raffinate와 extract 분포곡선을 겹치지 않도록 하여야 한다.

• Archives of Pharmacal Research
• /
• 제24권6호
• /
• pp.541-545
• /
• 2001

The evaluation of the anti-inflammatory analgesic and antipyretic activities of loxoprofen sodium given in intramuscular route was investigated as compared to oral application in rats and mice. The intramuscular $ED_{50}$ values of loxoprofen sodium in carrageenan edema and vascular permeability tests are 1.15 and 7.8 mg/kg, respectively, which represent more potent than in case of oral application. Its therapeutic effects in adjuvant arthritis were shown at 6 mg/kg l.m. and 3mg/kg p.o. Analgesic effect was shown to be more potent as given intramuscularly. Similar potency of antipyretic effects was shown in both administration routes. Considerably weak gastric damages were observed in intramuscular application.

• 한국산학기술학회논문지
• /
• 제15권1호
• /
• pp.396-401
• /
• 2014

본 논문에서는 록소프로펜 제제의 분석 시간을 단축하고 제품 출하 속도를 향상시키기 위하여 근적외부(NIR) 스펙트럼 측정법을 이용하여 기존에 사용하던 HPLC 방법과 상호 비교해 보고자 하였다. 제제학적으로 사용되는 다른 첨가제들과 함께 록소프로펜 혼합시료를 제조하고, NIR 분광광도계와 HPLC로 록소프로펜을 정량하고 평가하였다. 두 시험법의 밸리데이션 항목으로 특이성, 정확성 및 정밀성을 실시하였다. NIR 측정법이 검증되었고, 제약산업 분야의 제조공정 중 품질관리를 위한 적합한 결과를 얻었다. 결론적으로 록소프로펜을 분석하는데 있어서 NIR 측정법을 사용하면 기존의 HPLC 정량법을 NIR의 결과로 대치할 수 있을 것이다.

• 한국임상약학회지
• /
• 제7권2호
• /
• pp.73-80
• /
• 1997

The bioequivalence of two loxoprofen tablets between the $Loxonin^{TM}$ (Dong Hwa Pharmaceutical Co., Ltd.) and the $Lokpen^{TM}$ (Dong Il Pharmaceutical Co., Ltd.) was evaluated. 12 normal male volunteers (age $21\sim27$ years old) were divided into two groups and a randomized cross-over study was employed. After one tablet containing 60 mg of loxoprofen sodium anhydrous was orally administered, blood was taken at predetermined time intervals and the concentration of loxoprofen in serum was determined with an HPLC method using UV/VIS detector. The pharmacokinetic parameters ($C_{max},\;T_{max}$, and $AUC_t$) were calculated and ANOVA was utilized for the statistical analysis of parameters. The results showed that the differences in $C_{max},\;T_{max}$, and $AUC_t$ between two tablets were $1.13\%,\;0\%,\;and\;0.69\%$, respectively The powers (1-${\beta}$) for $C_{max},\;T_{max}$, and $AUC_t$ were $84.88\%,\;88.61\%,\;and\;84.81\%$, respectively Detectable differences ($\delta$) and confidence intervals were all less than $20\%$. All of these parameters met the criteria of KFDA for bioequivalence, indicating that $Lokpen^{TM}$ tablet is bioequivalent to $Loxonin^{TM}$ tablet.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 2001년도 추계학술대회 및 정기총회
• /
• pp.93-93
• /
• 2001

Loxoprofen sodium is an orally used anti-inflammatory, analgesic and antipyretic agent. For alleviation or inhibition of the pain symptoms regardless of referred or superficial pain, the prompt absorption of a drug and its immediate bioavailability might be generally required for a formulation or development of a new drug. Therefore, in intramuscular administration, its anti-inflammatory, analgesic, and antipyretic effects were evaluated compared with an oral administration in animals. The occurrence of gastric damages which is common in nonsteroidal anti-inflammatory drugs was also observed.